cyrilzakka/clinical-trials huggingface dataset:
Renal Physiology During Continuous Renal Replacement Therapy

Approximately 50% of patients in the intensive care unit (ICU) develop acute kidney injury (AKI) and more than 10% need dialysis. There is no treatment for AKI. Care is aiming for optimization of circulation and blood flow to the kidneys and avoiding nephrotoxic agents.

There is conflicting data concerning whether early or late dialysis is harmful for the kidneys. No one has examined the physiological changes in the kidney when starting dialysis and which blood pressure that leads to most optimal physiological conditions for the kidneys during dialysis. In this descriptive study of 20 ICU patients suffering from AKI we aim to investigate renal physiology when starting continuous renal replacement therapy (CRRT) and also at different target blood pressures using retrograde renal vein thermodilution technique. In parallel we will also investigate and validate this invasive method with contrast enhanced ultrasound of the kidneys.


Eligibility Criteria:
Inclusion Criteria:

AKI, according to KDIGO, stage 2 or 3 but with preserved urine production. Treated in the ICU at Sahlgrenska University Hospital Written, signed informed consent Male and female subjects ≥18 years

Exclusion Criteria:

Emergency need for dialysis Allergy to contrast media (used for CEUS)
Efficacy of Lower Limb Exercises on Overactive Bladder Symptoms in Patients With Multiple Sclerosis

The aim of the study (OVERACT_V1) is to verify if the isometric contraction of ankle plantarflexor and Hamstring muscles, induces a significant reduction of overactive bladder symptoms in patients with Multiple sclerosis.

The aim of the study (OVERACT_V1) is to verify if the isometric contraction of ankle plantarflexor and Hamstring muscles, induces a significant reduction of overactive bladder symptoms in patients with Multiple sclerosis. It's known that the electric stimulation of the Posterior Tibial nerve induces an improvement of overactive bladder symptoms through a modulation of spinal circuitry, which occurs with unknown mechanisms. The investigators' hypothesis is that the voluntary muscular activation may induce a modulation of the sacral root as long as the electric stimulation. 30 patients will be recruited within 2 years, since October 2017 through October 2019. This is a monocentric, randomized controlled , in single blind, not pharmacological study.

Eligibility Criteria:
Inclusion Criteria:

* Multiple Sclerosis Patients
* Urge score \>=2
* urinary daytime frequency \>=8
* stable overactive bladder symptoms for 6 months
* MRC ( Medical Research Council) scale of ankle plantarflexors and hamstrings \>=2
* signed informed consensus

Exclusion Criteria:

* FIM ( Functional Independence Measure) memory items \<=4
* impairment in registering bladder diary
* inclusion in other experimental study
* specific straightening during the suty period
* PVR \>= 200 ml ina single evaluation or PVR (post void residual) \>=150 in 4 evaluation (twice a day for 2 consecutive days)
* Urinary infections
* concomitant urological disease
* intrathecal baclofen pump
* SANS (Stoller Afferent Nerve Stimulation)
* modification of therapy for overactive bladder symptoms within three months before entering the study
Study of High Risk Non Invasive Prenatal Test Population

The investigator want to study the population of high risk (over 1/50) of Trisomy 21.

According to french guidelines, these patients needs to have a invasive test (such as amniocentesis) but some patients prefer to have a Non Invasive Prenatal Test, with a potential lack of information.


Eligibility Criteria:
Inclusion Criteria:

* Prenatal screening of Trisomy 21 \> 1/50 (high risk population)

Exclusion Criteria:

* No exclusion criteria
A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol

The purpose of this study is to determine the percentage of patients who would reach a cholesterol goal after atorvastatin treatment.


Eligibility Criteria:
Inclusion Criteria:

* Patients with high cholesterol eligible for treatment with baseline LDL-C level of less than or equal to 220 mg/dL
* Willingness to follow diet

Exclusion Criteria:

* Triglycerides less than or equal to 400 mg/dL
* Hemoglobin A1c \>10%
Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation

The purpose of this study is to determine if the antisialagogues (anti-salivary agents), Atropine and Glycopyrrolate, are effective in reducing hypersalivation when sedating patients with Ketamine for procedural sedation in the emergency department or abscess clinic. The investigators will measure salivary flow rate by collecting oral secretions by oral suctioning over a 30 minute time period starting with the administration of Ketamine. The investigators hypothesize that patients who receive either atropine or glycopyrrolate will have fewer oral secretions than patients who receive placebo.

Ketamine is a common sedation agent used in the pediatric emergency department for a variety of procedures, used in clinical practice since 1970. One potential side effect of Ketamine is hypersalivation, potentially leading to laryngospasms. To prevent hypersalivation (and reduce the potential for laryngospasms), an anti-salivary agent, such as Atropine, is commonly given in combination with Ketamine. Recently, however, the necessity of this practice has been brought into question. The consideration of using a different drug, glycopyrrolate, has been debated. The purpose of this study is to compare the effectiveness of each medication in addition to the placebo control.

Patients enrolled into this study must present to the emergency department or abscess clinic with the need to receive Ketamine as part of a sedation procedure (as determined by the treating physician). This study will randomize enrolled patients to receive double-blinded Atropine, Glycopyrrolate or placebo given 30 minutes prior to Ketamine. After Ketamine is administered, a trained medical person will suction the patient's mouth every 5 minutes for a total of 30 minutes, collecting all oral secretions. Total saliva production will be measured and salivary flow rates will be calculated and compared between each assigned group. Adverse events and complications will be monitored throughout the patient's stay in the emergency department or abscess clinic.

Eligibility Criteria:
Inclusion Criteria:

* Children age 6 months to 18 years (inclusive) presenting to Children's Medical Center Emergency Department or Abscess Clinic.
* Children whom the attending physician feels need procedural sedation with the intravenous medication, Ketamine.

Exclusion Criteria:

* Children who are ASA class III or greater.
* Children with an allergy or contraindication to ketamine, atropine or glycopyrrolate.
* Inability to tolerate oral suctioning.
* Any condition or situation whereby the patient would be unable to have his/her head turned to one side.
* Patient history of vomiting or diarrhea in the last 24 hours
* Patients who have taken an anti-sialogogue within the previous 24 hours.
* Patients that need to receive Midazolam or other benzodiazepines.
Effect of Perioperative Intravenous Lidocaine Infusion and Magnesium Infusion on the Functional Recovery After General Anesthesia in the Patients Undergoing Breast Mastectomy

Postsurgical pain is a relevant side effect following surgery which increases the risk of various complications and delays postoperative patient recovery. Among the many types of surgeries, mastectomy causes not only acute but also chronic pain in many patients. Therefore, it is important to control pain and increase patients' recovery satisfaction following many kinds of operations by using as small an opioid analgesic dose as possible and adding a nonopioid analgesic to reduce the side effects of narcotic analgesics. Among nonopioid analgesics, lidocaine and magnesium are drawing attention, having been shown to be helpful in controlling postoperative pain by lowering pain hypersensitivity to surgical stimuli. An intraoperative intravenous injection of lidocaine has been reported to improve postoperative pain control by reducing postoperative pain and opioid consumption. Another report showed that an intraoperative intravenous injection of lidocaine improved the quality of postoperative functional recovery after general anesthesia in a laparoscopic cholecystectomy patient. In addition, a review article on the effect of intraoperative intravenous injection of magnesium found it to be an effective analgesic that may be added to conventional opioid-based therapy because it generally reduces opioid consumption, decreases pain assessment for 24 hours after surgery, and lacks severe side effects in relation to magnesium administration. However, there has been insufficient research comparing the intraoperative intravenous injection of lidocaine or magnesium in terms of which is more helpful for general functional recovery and decreased postoperative pain. Recently, the scope of research on anesthesia has come to embrace postanesthetic recovery; to help patients return to daily life, the research trend is now shifting from the improvement or resolution of a specific symptom to the measurement of general recovery. A widely used method to measure postoperative recovery is the Quality of Recovery 40 (QoR-40) survey.

Therefore, in this study, the researchers investigated the intraoperative intravenous injection of lidocaine and the intravenous injection of magnesium to compare these drugs' helpfulness in the functional recovery of mastectomy patients after general anesthesia.


Eligibility Criteria:
Inclusion Criteria:

-Patients aged between 20 and 65 who have undergone mastectomy due to breast cancer and of American Society of Anesthesiologists (ASA) Physical Status Class 1 or Class 2

Exclusion Criteria:

* Patients experiencing pain for any cause or taking an analgesic
* Pregnant patients
* Patients with severe heart, kidney, or liver disease
* Patients with a psychiatric or neurological disorder
* Patients with a contraindication or allergic response to lidocaine
* Patients with a contraindication or allergic response to magnesium
Study of Glycopyrronium in Axillary Hyperhydrosis

The study is a randomized, double-blind, vehicle controlled, parallel group study, designed to assess the efficacy and safety of glycopyrronium topical wipes, once daily, compared to vehicle in subjects with axillary hyperhidrosis.

This is a randomized, double-blind vehicle controlled study to assess the efficacy and safety of glycopyrronium topical wipes compared to vehicle in subjects with axillary hyperhidrosis.

Safety will be assessed through lab tests, ECG, physical exams and vital signs.

Eligibility Criteria:
Inclusion Criteria:

* Male or female ≥ 9 years of age.
* Primary, axillary hyperhidrosis of at least 6 months duration
* Hyperhidrosis Disease Severity Scale (HDSS) of 3 or 4 at Baseline
* Axillary Sweating Daily Diary (ASDD) ≥ 4 at Baseline
* Sweat production of at least 50 mg over 5 minutes in each axilla assessed gravimetrically

Exclusion Criteria:

* Prior surgical procedure for hyperhidrosis.
* Prior axillary treatment with an anti-hyperhidrosis medical device (approved or investigational).
* Prior treatment with botulinum toxin (e.g., Botox®) for axillary hyperhidrosis within 1 year of Baseline/Day 1.
* Previous active treatment in the Dermira DRM04-HH01 or DRM04-HH02 clinical trials.
* Axillary use of nonprescription antiperspirants within 1 week or prescription antiperspirants within 2 weeks of Baseline.
* Subjects on new or regimens of psychotherapeutic medications that have changed within 2 months of baseline.
* Treatment with systemic anticholinergics within 4 weeks of the baseline visit unless dosing has been stable for at least 4 months.
* Other treatment with glycopyrrolate within 4 weeks prior to Baseline.
* Secondary axillary hyperhidrosis or presence of a condition that may cause secondary hyperhidrosis.
* History of Sjögren's syndrome or Sicca syndrome.
* History of glaucoma, inflammatory bowel disease, toxic megacolon, or febrile illness.
* Men with a history of urinary retention requiring catheterization due to prostatic hypertrophy or severe obstructive symptoms of prostatic hypertrophy.
* History or presence of ventricular arrhythmias, atrial fibrillation, atrial flutter.
* Other systemic diseases or active uncontrolled infections, or any other condition which, in the judgment of the Investigator, would put the subject at unacceptable risk for participation in the study.
Acute Myocardial Infarction in Native Versus Non-native Young Population in Saudi Arabia

A retrospective study collecting the data of young patients admitted with diagnosis of Acute Myocardial Infarction.

A retrospective study investigating young adults aged \<45 years for males and \<55 years for females admitted at Saud Al Babtain Cardiac Center with diagnosis of Acute Myocardial Infarction, determining its risk factors for Coronary Artery Disease (CAD) related to cultural characteristics and common positive consanguinity of parents as well as the prevalent diabetes and smoking.

Eligibility Criteria:
Inclusion Criteria:

* \<45 years old for male and \<55 years old for female
* patients admitted with diagnosis of Acute Myocardial Infarction

Exclusion Criteria:

* \<17 and \>55 years old male and female
* patients admitted with diagnosis other than Acute Myocardial Infarction.
Compliance of Antihypertensive Treatment Study (CAT Study)

Study Rational:

In general, chronic disease without symptoms such as hypertension, the treatment compliance is relative low and is difficult to increase. The low compliance is related to poor prognosis. There are many factors that effect to compliance of antihypertensive drug. Education is one factor that can be controlled by doctors. Therefore, in this study, the compliance of the patients in 3 groups of active training group, passive training group, and no training group (usual treatment group) will be compared to evaluate the effect of training for controlling of hypertension.

Objectives:

Primary objective - The compliance of each group for the antihypertensive drug is evaluated and compared.

The patients are allocated to three groups; active training group, passive training group, no training group (usual treatment group) and training is performed as described below.

* Active training group: Electronic Pill-Boxes with SMS service 1/week, training material provided
* Passive training group: Electronic Pill-Boxes ,Training material provided
* Usual treatment group: Electronic Pill-Boxes, maintain current treatment method

Secondary objective -

* Evaluate other factor that has effect on the compliance of antihypertensive drug.
* Evaluate the blood pressure lowering effect according to the compliance of antihypertensive drug.
* Evaluate the percentage of missed doses, the percentage of delayed doses, the percentage of multiple doses.
* Evaluate the effect of education on the compliance of antihypertensive drug.

Timelines FPFV : Jan, 2008 LPLV: Dec. 2008

Methodology:

This clinical trial is multi center, prospective, randomized, open, observational study.

This study is to compare the compliance for antihypertensive drugs according to different method of patient training and the observation period per patient is 6 month. There is no fixed visit date and the visits are made according to patient's periodic treatment schedules.

To come up with representative and reliable nation wide statistical data, from hospitals nation wide patient who receive drugs (ACE-I, ARB, β-Blocker, CCB, Diuretic) for blood pressure lowering purpose according to the prescription patterns of investigator will be registered.

Number of centers \& patients:

No. of centers: 20 general hospitals No. of patients: 1,062 patients

Eligibility Criteria:
Inclusion Criteria:

* Patient diagnosed as hypertension.
* Hypertension patients diagnosed and treated but not meeting the target blood pressure. (Target blood pressure: SBP\<140mmHg and DBP\<90mmHg. In case having concomitant disease JNC-VII guideline is followed)
* Patients age over 18

Exclusion Criteria:

* Patients with severe chronic disease
* Patients scheduled for operation within 6 month period.
* Patients currently participating in other clinical study.
* Pregnant, nursing patient and patient with potential to be pregnant.
* Patient who can not or has no intension to participate in compliance check.
CNS Growth Factors Release and Changes in the Inflammatory Environment in Response to Electrical Stimulation in Subjects With Inflammatory Myelopathies

This research is being done to see how different amounts of Functional Electrical Stimulation (FES) affect cycling on factors in blood and spinal cord in people with spinal cord inflammation.

FES cycling is a method of applying low level electrical currents to the leg and buttock muscles to cause the weakened or paralyzed muscles to contract and produce a cycling motion of the legs. The FES cycling in this study will be done through a device called the RT300-SL Cycle Ergometer (RT300).

Although this device has been cleared by the Food and Drug Administration (FDA) for use by individuals with neurological disorders, we are trying to find out the best way to use it in order to obtain the greatest results.

Eligibility Criteria:
Inclusion Criteria:

* Male, Female, age 18-65, all ethnic groups
* History of inflammatory myelopathy with onset at least 3 months prior
* No FES ergometer (i.e. RT300 or equivalent) use within 1 month
* Subject is medically stable, with no recent (1 month or less) inpatient admission for acute medical or surgical issues
* Subject is legally able to make own health care decisions
* Access to telephone with texting capabilities
* English language proficiency

Exclusion Criteria:

* Cardiovascular disease as defined by previous myocardial infarction, unstable angina, requirement for anti platelet agents, congestive heart failure, or stroke New York Heart Association (NYHA) Class III or IV, history of arrhythmia with hemodynamic instability.
* Uncontrolled hypertension (resting systolic BP\>160mmHg or diastolic BP \>100mmHg consistently)
* Concurrent lower motor neuron disease such as peripheral neuropathy that would exclude lower extremity electrical excitability
* Unstable long bone fractures of the lower extremities
* Subjects who are unwilling to agree to two cerebrospinal fluid (CSF) examinations (lumbar punctures)
* Presence of cardiac pacemaker and/or defibrillator
* Presence of cancer
* History of epileptic seizures
* Subjects having a Stage 2 or greater sacral decubitus ulcer
* Women who are pregnant
* Active drug or alcohol use or dependence
Endometrial Injury and Implantation Rates Before First ICSI Cycle

Midluteal single endometrial strip will be taken using a Novak curett under general anasthesia to avoid discomfort and cramping and to proceed to cervical dilatation in case of forbidden cervix, the step that will be beneficial to embryo transfer procedure.

Controller ovarian hyperstimulation; will be done using the long luteal phase agonist protocol and the short protocol(as judged by patient,s age ovarian reserve judged by day 3 FSH and antral follicular count and previous history of ovarian response).

Ovarian response will be monitored by vaginal ultrasound and HCG will be given when when there is \>=1 follicle \>=18 mm. and \>=3 follicles \>=16 mm. Ultasound guided oocyte retrieval will be carried out 35 hours later. Embryo transfer will be performed on day 2 or day 3 after oocyt retrieval according to number and quality of embryos.

Embryo transfer will be carried out under trans-abdominal ultrasound guidance pregnancy test will be done using qualitative blood HCG detection 2 weeks after the embryo transfer.


Eligibility Criteria:
Inclusion Criteria:

1. subfertile women indicated for ICSI.
2. normal uterine cavity demonstrated by transvaginal ultrasound and hystrogram.
3. FSH\<10mIU/mL on day 3 of her cycle.

Exclusion Criteria:

1. presence of endometrial polyp or fibroid distorting the uterine cavity.
2. hydrosalpinx.
3. ICSI carried out for preimplantation genetic diagnosis.
4. FSH\>10mIU\\mL.
Comparing Effect of Hylorunic Acid and Lipid-coated Carbomer Gel on Dry Eyes After Phacoemulsification in DP

In this research checked the curative effect of two different artificial tears on dry eyes after phacoemulsification was checked. In research, the randomized control trial methodology is used


Eligibility Criteria:
Inclusion Criteria:

* Patients aged 50-70
* Both gender male /female

Exclusion Criteria:

* Patients who have acute dry eye condition before phacoemulsification cataract surgery.
Vestibular Extraction Technique (VET): a Novel Atraumatic Extraction Technique

study proposes an alternative atraumatic tooth extraction procedure; Apically achieved exodontia, which might offer an alternative to the conventional incisal exodontia, whilst providing minimum tissue trauma and subsequently maximum marginal tissue preservation.

A sample of 26 patients that received the extraction therapy For Group (A) patients, Atraumatic extractions using periotomes followed by conventional forceps were performed.

For Group (B) patients, the novel technique of Vestibular Root Extraction was performed to the sample group's hopeless teeth.

Eligibility Criteria:
Inclusion Criteria:

* Single non-adjacent hopeless maxillary anterior teeth
* Type II socket)
* Intact overlying soft tissues.
* Adequate palatal and at least 3 mm apical bone

Exclusion Criteria:

* Smokers
* Pregnant females
* Patients with systemic diseases
A Study to Investigate Bio Product Laboratory Ltd (BPL's) Factor X in the Prophylaxis of Bleeding in Children <12 Years

The primary objective of the study is to assess the efficacy of FACTOR X in the prevention of bleeding when given as routine prophylaxis over 12 months.

The secondary objectives of the study are:

1. To assess the pharmacokinetics of FACTOR X after a single dose of 50 IU/kg.
2. To assess the safety of FACTOR X when given as routine prophylaxis over 6 months (26 weeks).


Eligibility Criteria:
Inclusion Criteria

1. Children with hereditary severe or moderate FX deficiency (FX:C \<5 IU/dL), based on their lowest reliable FX:C recorded.
2. Children under 12 years old, whose parent/guardian has given informed consent.
3. Children with a history of severe bleeding e.g.: intracranial haemorrhage, before starting prophylactic therapy, OR a mutation in the F10 gene causing a documented severe bleeding phenotype.

Exclusion Criteria

1. Children must not suffer from clinically significant liver disease, renal disease, or other coagulopathy or thrombophilia
2. Children must have no history or suspicion of inhibitors to factor X.
3. Children who have known or suspected hypersensitivity to the investigational medicinal product or its excipients.
4. Children with a history of unreliability or non-cooperation.
5. Children who are participating or have taken part in another trial within the last 30 days.
6. Children planning more than 4 weeks' continuous absence from the locality of the investigational site, between the Screening Visit and the End of Study Visit at approximately 6 months (26 weeks) post-Baseline.